Abstract:Background: The incidence of post-stroke depression (PSD) may be higher in patients with cancer-associated ischemic stroke (CAIS). The pathogenesis of PSD is mainly related to the emotional injury of stroke and the inability of neurons to effectively repair. This study aims to explore the clinical significance of serum neuron-specific enolase (NSE), brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) expression levels in CAIS patients. Methods: Clinical data of 106 patients with CAIS admitted to Jinhua Guangfu Oncology Hospital from January 2012 to December 2022 were retrospectively analyzed. Serum levels of NSE, BDNF and CNTF were measured in all patients after admission. Depression screening was performed by Hamilton Depression Scale-17 (HAMD-17) three months after intravenous thrombolysis. Patients with HAMD-17 score >7 were included in the PSD group (n = 44), and patients with HAMD-17 score ≤7 were included in the non-PSD group (n = 62). The general data and serum levels of NSE, BDNF and CNTF were compared between the two groups. According to HAMD-17 scores, patients in PSD group were further divided into mild depression group (8-16 points), moderate depression group (17-23 points) and severe depression group (≥24 points), and the serum levels of NSE, BDNF and CNTF were compared among the three groups. Pearson's correlation test was used to analyze the correlation between HAMD-17 scores and serum NSE, BDNF and CNTF levels in PSD patients. Logistic regression model was used to determine the influencing factors of PSD in CAIS patients. Receiver operating characteristic (ROC) curve was plotted to analyze the predictive efficacy of serum NSE, BDNF, CNTF and their combination on PSD. Results: Among 106 CAIS patients, the incidence of PSD was 41.51% (44 cases), including 19 patients with mild PSD (43.18%), 14 patients with moderate PSD (31.82%), and 11 patients with severe PSD (25.00%). There were statistically significant differences in negative life events and complications after thrombolytic therapy between PSD and non-PSD patients (p < 0.05). The serum NSE level in PSD group was significantly higher than that in non-PSD group, and the serum BDNF and CNTF levels were notably lower than those in non-PSD group (all p < 0.001). The serum levels of NSE, BDNF and CNTF in patients with different severity of PSD were statistically significant (all p < 0.001). HAMD-17 scores in PSD patients were positively correlated with serum NSE levels (r = 0.676, p < 0.001) and negatively correlated with serum BDNF and CNTF levels (r = -0.661, p < 0.001; r = -0.401, p = 0.007, respectively). By binary logistic regression analysis, the levels of serum NSE, BDNF and CNTF were independent influencing factors for PSD in CAIS patients, among which NSE was a risk factor (odds ratio (OR) >1, p < 0.05), BDNF and CNTF were protective factors (OR <1, p < 0.05). Conclusion: This study reveals for the first time that the levels of serum NSE, BDNF and CNTF are closely related to the occurrence and development of PSD in CAIS patients. In clinical CAIS patients with abnormal changes in the above indicators, in addition to anti-tumor treatment and improvement of neurological deficit symptoms, attention should also be paid to the symptoms of psychological disorders.

Serum Levels of FGF21, β-Klotho, and BDNF in Stable Coronary Artery Disease Patients With Depressive Symptoms: A Cross-Sectional Single-Center Study

Prevalence and Predisposing Factors of Depressive Symptoms in Patients with Stable Coronary Artery Disease: a Cross-Sectional Single-Center Study

The Predictive Value of Mbdnf for Major Adverse Cardiovascular Events in Stable Coronary Artery Disease Patients with Depressive Symptoms: A Single-Center, 5-Year Follow-Up Study

Independent Impact of Brain-Derived Neurotrophic Factor on Cardiovascular Prognosis in Coronary Heart Disease Patients: A Prospective Cohort Study

Alterations of irisin, adropin, preptin and BDNF concentrations in coronary heart disease patients comorbid with depression

The association between levels of brain‐derived neurotrophic factor and comorbid depression in patients with cardiovascular disease: The Framingham Heart Study

Serum BDNF and GDNF in Chinese male patients with deficit schizophrenia and their relationships with neurocognitive dysfunction

Association Between Depressive Symptoms and Serum Brain-Derived Neurotrophic Factor Levels in Patients With First-Episode and Drug-Naïve Schizophrenia

Peripheral Blood BDNF-TrkB Signaling in First-Episode, Drug-Free Patients with Major Depressive Disorder and Schizophrenia.

Serum brain derived neurotrophic factor levels and post-stroke depression in ischemic stroke patients

Serum Levels of Brain-Derived Neurotrophic Factor Are Associated with Depressive Symptoms in Patients with Systemic Lupus Erythematosus

The expression of SAH, IL-1β, Hcy, TNF-α and BDNF in coronary heart disease and its relationship with the severity of coronary stenosis

The Relationship between Level of BDNF in Serum and Depressive Symptoms and Cognitive Dysfunction of Patients with Major Depression

Depressive Symptoms in Schizophrenia Patients: A Possible Relationship Between SIRT1 and BDNF.

Potential Biomarkers for Depression Associated with Coronary Artery Disease: A Critical Review

Vitamin D status in chronic dialysis patients with depression: a prospective study

The Value of Plasma Fibrillin-1 Level in Patients with Spontaneous Coronary Artery Dissection.

Serum Brain-derived Neurotrophic Factor Levels in Post-Stroke Depression.

Serum Levels and Clinical Significance of NSE, BDNF and CNTF in Patients with Cancer-associated Ischemic Stroke Complicated with Post-stroke Depression

Coronary artery disease and depression: possible role of brain-derived neurotrophic factor and serotonin transporter gene polymorphisms

Additive Relationship Between Serum Fibroblast Growth Factor 21 Level and Coronary Artery Disease